Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:tafamidis
|
| gptkbp:approvalYear |
2019
|
| gptkbp:ATCCode |
N07XX08
|
| gptkbp:brand |
gptkb:Vyndamax
|
| gptkbp:CASNumber |
594839-88-0
|
| gptkbp:chemicalFormula |
C21H18O6N2
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:form |
capsule
20 mg 61 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Vyndaqel
|
| gptkbp:indication |
transthyretin amyloid cardiomyopathy
transthyretin familial amyloid polyneuropathy |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
transthyretin stabilizer
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
abdominal pain headache urinary tract infection |
| gptkbp:status |
FDA approved
|
| gptkbp:bfsParent |
gptkb:tafamidis
|
| gptkbp:bfsLayer |
8
|